Target intelligence / Profile preview

Serine beta-lactamase (Class A, C, or D)

Molecular classification
Enzyme, Hydrolase, Serine hydrolase, DD-peptidase superfamily
01

Overview

Serine beta-lactamases (classes A, C, and D) are a broad family of enzymes found in bacteria that confer resistance to β-lactam antibiotics by catalyzing the hydrolysis of the β-lactam ring using an active-site serine residue[2][5]. These enzymes are genetically diverse, structurally conserved around their catalytic mechanism, and classified according to molecular sequence and function. Their clinical importance is highlighted by their role in antibiotic resistance in major Gram-negative and some Gram-positive pathogens, leading to significant therapeutic challenges and driving the development of β-lactamase inhibitors[4][2][5][7]. Note: "Class A, C, and D serine β-lactamases" as a term is a superclass rather than a single canonical drug/protein target. Individual genes/proteins (e.g., TEM-1, OXA-1, AmpC) should be referenced for precise drug-target annotation[2][5][7]. These classes are distinct from class B β-lactamases (metallo-β-lactamases), which use a zinc ion for catalysis, not serine[2][5][6].

Other names
β-lactamase (class A, C, D)Serine β-lactamaseAmbler class A/C/D β-lactamaseAmpC (class C)OXA (class D)TEMSHVKPC
02

Mechanism of action

Targeted drugs can inhibit the enzyme's serine-based hydrolysis of the β-lactam ring (e.g., covalent acylation of active-site serine by inhibitors). Some drugs evade hydrolysis due to poor recognition (e.g., certain cephamycins or carbapenems).

03

Biological functions

Hydrolysis of β-lactam antibioticsAntibiotic resistanceBacterial cell survival under antibiotic stress
04

Disease associations

Infection (including multi-drug resistant bacterial infections; major role in resistance to penicillins, cephalosporins, carbapenems)
05

Safety considerations

Rapid emergence of resistance (new enzyme variants)Limited inhibitor options for some β-lactamases (e.g., class C and some class D enzymes are poorly inhibited by classic inhibitors)Cross-resistance among multiple β-lactams due to broad substrate profiles
06

Interacting drugs

β-lactam antibiotics (e.g., penicillins, cephalosporins, carbapenems, monobactams)

1 more in the full profile.

07

Biomarkers

Presence of serine β-lactamase genes (e.g., TEM, SHV, OXA, AmpC) by PCR or sequencing as biomarkers for resistance and therapy guidance

Beyond the preview

Go deeper on Serine beta-lactamase (Class A, C, or D).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serine beta-lactamase (Class A, C, or D).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call